Published in J Clin Endocrinol Metab on April 09, 2010
Adverse events associated with testosterone administration. N Engl J Med (2010) 10.94
Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol (2013) 2.47
Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab (2011) 1.71
Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci (2011) 1.43
Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian J Androl (2015) 1.39
Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol (2014) 1.33
Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev (2012) 1.01
Endocrinology of the aging male. Best Pract Res Clin Endocrinol Metab (2011) 0.99
Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the framingham heart study. Diabetes Care (2011) 0.99
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male (2015) 0.97
Testosterone plus low-intensity physical training in late life improves functional performance, skeletal muscle mitochondrial biogenesis, and mitochondrial quality control in male mice. PLoS One (2012) 0.86
Sex differences in the association between serum levels of testosterone and frailty in an elderly population: the Toledo Study for Healthy Aging. PLoS One (2012) 0.85
Reciprocal relations between physical disability, subjective health, and atrial fibrillation: the Framingham Heart Study. Am Heart J (2013) 0.85
Androgen effects on skeletal muscle: implications for the development and management of frailty. Asian J Androl (2014) 0.83
Serum sex steroid hormones and frailty in older American men of the Third National Health and Nutrition Examination Survey (NHANES III). Aging Male (2012) 0.83
Higher testosterone levels are associated with less loss of lean body mass in older men. J Clin Endocrinol Metab (2011) 0.82
Multiple hormonal dysregulation as determinant of low physical performance and mobility in older persons. Curr Pharm Des (2014) 0.82
Immunological and mass spectrometric assays of SHBG: consistent and inconsistent metabolic associations in healthy men. J Clin Endocrinol Metab (2013) 0.82
Oxidative stress, testosterone, and cognition among Caucasian and Mexican-American men with and without Alzheimer's disease. J Alzheimers Dis (2014) 0.81
Endocrine determinants of incident sarcopenia in middle-aged and elderly European men. J Cachexia Sarcopenia Muscle (2015) 0.80
Sarcopenia and Androgens: A Link between Pathology and Treatment. Front Endocrinol (Lausanne) (2014) 0.79
Diagnosis and Treatment of Low Testosterone among Patients with End-Stage Renal Disease. Semin Dial (2014) 0.78
Sex differences in the association of fasting and postchallenge glucose levels with grip strength among older adults: the Rancho Bernardo Study. BMJ Open Diabetes Res Care (2015) 0.77
Effects of Testosterone Supplementation for 3-Years on Muscle Performance and Physical Function in Older Men. J Clin Endocrinol Metab (2016) 0.75
Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case-control study. J Cachexia Sarcopenia Muscle (2016) 0.75
Low testosterone must explain diminished physical performance in the elderly--right? J Clin Endocrinol Metab (2010) 0.75
Testosterone deficiency in the aging male. Ther Adv Urol (2016) 0.75
Thoracic Kyphosis and Physical Function: The Framingham Study. J Am Geriatr Soc (2017) 0.75
A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol (1994) 30.72
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med (1995) 20.53
Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health (1951) 20.27
An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol (1979) 18.84
A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab (1999) 10.64
Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc (2006) 8.75
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
A Guttman health scale for the aged. J Gerontol (1966) 7.87
Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab (2001) 7.53
Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985) (2003) 5.73
Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA (2008) 4.83
Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab (2002) 4.46
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med (1996) 4.10
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
Role of endocytosis in cellular uptake of sex steroids. Cell (2005) 3.49
Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab (2006) 3.46
Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab (2004) 3.02
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab (1999) 2.79
Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab (2001) 2.79
Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab (2004) 2.47
Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev (1999) 2.39
Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA (2000) 2.26
Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 2.08
Quality indicators for the management and prevention of falls and mobility problems in vulnerable elders. Ann Intern Med (2001) 2.00
Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism (1997) 1.97
Analysis of change in self-reported physical function among older persons in four population studies. Am J Epidemiol (1996) 1.86
Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology (2003) 1.74
Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med (2006) 1.72
Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab (1996) 1.70
Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol (2003) 1.66
Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab (2003) 1.57
Mobility limitations in the Medicare population: prevalence and sociodemographic and clinical correlates. J Am Geriatr Soc (2005) 1.52
Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol (1997) 1.52
Mobility limitations and cognitive deficits as predictors of institutionalization among community-dwelling older people. Gerontology (2006) 1.42
The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf) (2005) 1.41
Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab (2009) 1.40
Tests of muscle strength and physical function: reliability and discrimination of performance in younger and older men and older men with mobility limitations. J Am Geriatr Soc (2008) 1.37
Age, gender, and muscular strength. J Gerontol A Biol Sci Med Sci (1995) 1.26
Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab (2002) 1.26
Association between testosterone and estradiol and age-related decline in physical function in a diverse sample of men. J Am Geriatr Soc (2008) 1.24
Testosterone, sex hormone-binding globulin, and frailty in older men. J Am Geriatr Soc (2007) 1.24
Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab (2003) 1.23
Katz index of independence in ADL. Reliability and validity in short-term care. Scand J Rehabil Med (1984) 1.23
Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem (2009) 1.20
Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways. Endocrinology (2008) 1.20
Health-related quality of life in older adults at risk for disability. Am J Prev Med (2007) 1.16
Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab (2003) 1.16
Sex hormones and frailty in older men: the osteoporotic fractures in men (MrOS) study. J Clin Endocrinol Metab (2009) 1.14
Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab (2002) 1.13
The influence of aging on plasma sex hormones in men: the Telecom Study. Am J Epidemiol (1992) 1.10
Evaluation of movement speed and reaction time as predictors of all-cause mortality in men. J Gerontol A Biol Sci Med Sci (2005) 1.08
The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids (2008) 1.03
Test-retest reliability of self-reported disability measures in older adults. J Am Geriatr Soc (1997) 0.99
Low testosterone levels and decline in physical performance and muscle strength in older men: findings from two prospective cohort studies. Clin Endocrinol (Oxf) (2007) 0.97
Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab (2005) 0.90
CDC project on standardizing steroid hormone measurements. Steroids (2008) 0.88
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Adverse events associated with testosterone administration. N Engl J Med (2010) 10.94
Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension (2004) 8.27
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med (2010) 7.03
Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA (2012) 6.96
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med (2004) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Aortic stiffness, blood pressure progression, and incident hypertension. JAMA (2012) 6.01
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc (2011) 5.96
Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation (2008) 5.95
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging (2005) 5.84
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Genomewide association studies of stroke. N Engl J Med (2009) 5.29